PolyPid Ltd.
PYPD
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$32M
▼ -17.7% YoY
Op. Margin
–
ROIC
-167.65%
▼ -15.4pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$28M
▼ -27.5% YoY
Op. Cash Flow (FY)
-$28M
▼ -26.9% YoY
Net Debt
-$10M
Net Cash Position
Cash & Equiv.
$13M
Continue Research
Peers
Biotechnology · Pick stocks to compare with PYPD
PolyPid (PYPD) in three numbers
Questions about PolyPid
Is PolyPid a high-quality business?
PolyPid scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$10M, and its weakest is return on capital at -167.6%. The Quality tab shows every check against its target.
Does PolyPid (PYPD) pay a dividend?
No. PolyPid (PYPD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PYPD
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.